Impact of magnesium deficiency on the quality of life of women using hormonal contraception

Objective of the study: estimate the prevalence of magnesium deficiency (MD) in women using hormonal contraception (HC), who are enrolled in the MAGYN2 study, determine the clinical features of MD and the efficacy of Magne B6 Forte in replenishing magnesium deficiency and improving the patients’ quality of life.Material and methods: 1,904 women using HC were examined. At stage I,the prevalence of DMwas assessed on the basis of the MDQ questionnaire and/or serum magnesium levels were determined. Then the patients were divided into two groups: I – without magnesium deficiency (n = 996) and II – with identified MD (n = 908) during the study. The following parameters were determined: clinical symptomatology caused by MD, and the women’s quality of life using the WHOQOL-BREF questionnaire. At stage II, patients with MD received Magne B6 Forte for 4 weeks with an assessment of its efficacy. Results: The prevalence of MD in the population of patients taking HA is 47.7%. The most severe manifestations of MD included irritation, increased fatigue, chronic stress state. The clinical efficacy of Magne B6 Forte was confirmed by increased serum magnesium levels (from 0.67 ± 0.09 to 0.79 ± 0.26 mmol/L, p< 0.001), normalization of the MDQ score (from 42.5 ± 11, 4 to 22.7 ± 14.9 points, p< 0.001), double reduction of severity of more than half the symptoms of MD, improved quality of life in the range of 20 to 32% in 5 domains of the WHOQOL-BREF questionnaire. Conclusion: The use of Magne B6 Forte in women using HC helps to reduce symptoms of MD and improve the quality of life.

1. Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16 000 individuals. Magnes Res, 2001, 14(4): 283-290.

2. Serov V.N., Baranov I.I., Blinov D.V. i dr. Rezul’taty issledovaniya defitsita magniya u patsiyentok s gormonal’no-zavisimymi zabolevaniyami. Akusherstvo i ginekologiya, 2015, 6: 91-97.

3. Golovanova V.A., Strokova O.A. Funktsional’noye sostoyaniye reproduktivnoy sistemy molodykh zhenshchin v usloviyakh defitsita vita-minov antioksidantnogo kompleksa. Vestnik Orenburgskogo gosudarstvennogo universiteta, 2011, 16(135): 261-263.

4. Gromova O.A., Serov V.N., Torshin I.YU. Magniy v akusherstve i ginekologii: istoriya primeneniya i sovremennyye vzglyady. Trudnyy patsiyent, 2008, 8(6): 20-28.

5. Dante G, Vaiarelli A, Facchinetti F. Vitamin and mineral needs during the oral contraceptive therapy: a systematic review. Int J Reprod Contracept Obstet Gynecol, 2014, 3(1): 1-10.

6. Palmery M, Saraceno A, Vaiarelli A, Carlomagno G. Oral contraceptives and changes in nutritional requirements. Eur Rev Med Pharmacol Sci, 2013, 17(13): 1804-1813.

7. Макацария А.Д., Дадак К., Бицадзе В.О., Солопова А.Г., Хамани Н.М. Клинические особенности у пациенток с гормонально-зависимыми состояниями и дефицитом магния. Акушерство и гинекология, 2017, 5: 124-131.

8. Gromova O.A., Limanova O.A. Defitsit magniya i sudorogi myshts u beremennykh: vozmozhnosti terapii (kliniko-farmakologicheskaya lektsiya). Ginekologiya, 2014, 2: 70-77.

9. Magne B6® forte (Magne B6® forte): Tabletki, pokrytyye plenochnoy obolochkoy. Instruktsiya po meditsinskomu primeneniyu. RLS, 2016. URL: http: //www.rlsnet.ru/.

10. Spasov A.A. Magniy v meditsinskoy praktike. Volgograd, 2000. 272 s.

11. The World Health Organization Quality of Life (WHOQOL)-BREF © World Health Organization 2004. URL: http: //www.who. int/.

12. Orlova S.V. Khelatnyye kompleksy v nutritsiologii i diyetologii. Izd. 3-ye, pererab. i dop. M., 2007. 72 s.

13. Serov V.N., Kerimkulova N.V., Torshin I.YU. i dr. Zarubezhnyy i rossiyskiy opyt primeneniya magniya v akusherstve i ginekologii s pozitsiy dokazatel’noy meditsiny. Voprosy ginekologii, akusherstva i perinatologii, 2012, 4: 62-72.

14. Stanton MF, Lowenstein FW. Serum magnesium in women during pregnancy, while taking contraceptives, and after menopause. J Am Col Nutrition, 2013, 6(4): 313-319.

15. Budanov P.V. Lecheniye predmenstrual’nogo sindroma: sovremennyye predstavleniya i perspektivy. Trudnyy patsiyent, 2012, 10(2–3): 34-37.

16. Nedogoda S.V. Rol’ preparatov magniya v vedenii patsiyentov terapevticheskogo profilya. Lechashchiy Vrach, 2009, 6: 16-19.

17. Mubarakshina O.A. Osobennosti primeneniya preparatov mag-niya beremennymi zhenshchinami. Farmateka. 2013, 18: 2-5.

18. Torshin I.YU., Gromova O.A. Mekhanizmy antistressovogo i antidepressivnogo deystviya magniya i piridoksina. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2009, 109(11): 107-111.

19. Chekman I.S., Gorchakova N.A., Nikolay S.L. Magniy v meditsine. Kishinev, 1992. 101 s.

20. Gunther T. The biochemical function of Mg 2+ in insulin secretion, insulin signal transduction and insulin resistance. Magnes. Res., 2010, 23(1): 5-18.

21. Torshin I.YU., Gromova O.A. Displaziya soyedinitel’noy tkani, kletochna-ya biologiya i molekulyarnyye mekhanizmy vozdeystviya magniya. RMZH, 2008, 16(4): 230-238.

22. Palmery M, Saraceno A, Vaiarelli A, Carlomagno G. Oral contraceptives and changes in nutritional requirements. European Review for Medical and Pharmacological Sciences, 2013, 17: 1804-1813.

23. Akinloye O et al. Effects of Contraceptives on Serum Trace Elements, Calcium and Phosphorus Levels. West Indian Medical Journal, 2011 Jun, 60(Issue 3): 308-315.

24. Morris MS, Picciano MF, Jacques PF, Selhub J. Plasma pyridoxal 5’-phosphate in the US population: the National Health and Nutrition Examination Survey, 2003-2004. Am J Clin Nutr, 2008, 87: 1446-1454.

25. Lussana F, Zighetti ML, Bucciarelli P, Cugno M, Cattaneo M. Blood levels of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared to non-users. Thromb Res, 2003, 112: 37-41.

26. Hameed A, Majeed T, Rauf S, Ashraf M, Jalil MA, Nasrullah M, Hussan A, Noreen R. Effect of oral and injectable contraceptives on serum calcium, magnesium and phosphorus in women. J Ayub Med Coll Abbottabad, 2001, 13: 24-25.

27. Stanton MF, Lowenstein FW. Serum magnesium in women during pregnancy, while taking contraceptives,and after menopause. J Am Coll Nutr, 1987, 6: 313-319.

28. Olatunbosun DA, Adeniyi FA, Adadevoh BK. Effect of oral contraceptives on Serum magnesium levels. Int J Fertil, 1974, 19: 224-226.

29. Blum M, Kitai E, Ariel Y, Schnierer M, Bograd H. Oral contraceptive lowers serum magnesium. Harefuah, 1991, 121: 363-364.

30. Orley J, Kuyken W. The Development of the World Health Organization Quality of Life Assessment Instrument (the WHOQOL). In: Quality of Life: International Perspectives. Division of Mental Health, World Health Organization. Proceedings of the Joint-Meeting Organized by the World Health Organization and the Fondation IPSEN in Paris, July 2–3, 1993: 41-57.

31. Protsenko AS, Abishev RE. Sovremennyye tendentsii otsenki effektivnosti meditsinskoy pomoshchi cherez kriteriy kachestva zhizni. Sovremennaya meditsina: tendentsii razvitiya: mat. mezhdunar. nauch.-prakt. konf., 2 aprelya 2012, Novosibirsk. Novosibirsk: Sibirskaya assotsiatsiya konsul’tantov, 2012. 132 s.

32. Blinov D.V., Zimovina U.V., Sandakova Ye.A., Ushakova T.I. Defitsit magniya u patsiyentok s gormonal’no-zavisimymi zabolevaniyami: farmakoepidemiologicheskiy profil’ i otsenka kachestva zhizni. Sovr. Farmakoekonomika i Farmakoepidemiologiya, 2015, 2: 16-24.

33. Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception, 2007, 76(4): 267-272.

34. Mohammad-Alizadeh-Charandabi S et al. The effect of multivitamin supplements on continuation rate and side effects of combined oral contraceptives. Eur J Contracept Reprod Health Care, 2015, 20(5): 361-371.

35. López-González B, Molina-López J, Florea DI еt al. Association between magnesium-deficient status and anthropometric and clinical-nutritional parameters in pos-menopausal women. Nutr Hosp, 2014, 29(3): 658-664.

36. Stanisławska M, Szkup-Jabłońska M, Jurczak A et al. The Severity of Depressive Symptoms vs. Serum Mg and Zn Levels in Postmenopausal Women. Biol Trace Elem Res, 2014, 157(1): 30-35.

37. Derom ML, Sayón-Orea C, Martínez-Ortega JM еt al. Magnesium and depression: a systematic review. Nutr Neurosci, 2012, 16: 191-206.

38. Dadak K. Magnesium deficiency in obstetrics and gynecology. Akusherstvo, ginekologiya i reproduktsiya, 2013, 7(2): 6-14.

39. Voznesenskaya N.V., Kozyreva Ye.V., Kasymova D.R., Razubayeva S.N. i dr. Psikhologicheskiy status zhenshchin s reproduktivnymi problemami v anamneze i yego svyaz’ s defitsitom magniya. Ul’yanovskiy mediko-biologicheskiy zhurnal, 2016, 1: 88-95.

40. Torshin I.YU., Gromova O.A. Ekspertnyy analiz dannykh v molekulyarnoy farmakologii. M.: NTSNMO, 2012. 747 s.